In consideration of the protective effects of galectin-3 in IBD, galectin-3 antagonists, which are currently being tested as therapeutic options to improve renal and liver fibrosis, are not recommended for patients with PSC-IBD. This evidence concerns the gene LGALS3 and inflammatory bowel disease.